These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1533693)

  • 1. [Significance of blood purification in cancer therapy].
    Toge T
    Nihon Rinsho; 1992 Jan; 50 Suppl():357-63. PubMed ID: 1533693
    [No Abstract]   [Full Text] [Related]  

  • 2. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells?
    Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW
    Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making and circumventing tolerance to cancer.
    Kammertoens T; Blankenstein T
    Eur J Immunol; 2009 Sep; 39(9):2345-53. PubMed ID: 19634191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers].
    Kitsukawa K
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1448-54. PubMed ID: 2543306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale of combined modality therapy for cancer.
    Martin DS; Fugmann R; Stolfi R; Hayworth P
    Cancer Chemother Rep 2; 1974 Mar; 4(1):13-24. PubMed ID: 4363650
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.
    Wada J; Yamasaki A; Nagai S; Yanai K; Fuchino K; Kameda C; Tanaka H; Koga K; Nakashima H; Nakamura M; Tanaka M; Katano M; Morisaki T
    Anticancer Res; 2008; 28(4C):2401-8. PubMed ID: 18751426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for infection and malignancy in children with cancer.
    Frost JD; Sondel PM
    Adv Pediatr; 1994; 41():385-413. PubMed ID: 7992692
    [No Abstract]   [Full Text] [Related]  

  • 8. Marrying immunotherapy with chemotherapy: why say IDO?
    Muller AJ; Prendergast GC
    Cancer Res; 2005 Sep; 65(18):8065-8. PubMed ID: 16166276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing adoptive immunotherapy of cancer.
    Westwood JA; Berry LJ; Wang LX; Duong CP; Pegram HJ; Darcy PK; Kershaw MH
    Expert Opin Biol Ther; 2010 Apr; 10(4):531-45. PubMed ID: 20132063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulation by cancer chemotherapeutic agents and antineoplastic activity.
    Spreafico F; Mantovani A
    Pathobiol Annu; 1981; 11():177-95. PubMed ID: 6460217
    [No Abstract]   [Full Text] [Related]  

  • 11. Functional control of regulatory T cells and cancer immunotherapy.
    Wang RF
    Semin Cancer Biol; 2006 Apr; 16(2):106-14. PubMed ID: 16423537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation.
    Whelan MC; Casey G; MacConmara M; Lederer JA; Soden D; Collins JK; Tangney M; O'Sullivan GC
    Cancer Gene Ther; 2010 Jul; 17(7):501-11. PubMed ID: 20186173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory T cells, as a target in anticancer immunotherapy.
    Enokida T; Nishikawa H
    Immunotherapy; 2017 Jun; 9(8):623-627. PubMed ID: 28653572
    [No Abstract]   [Full Text] [Related]  

  • 14. A new type of liposome for electrochemical treatment of cancer: the lipogelosomes.
    Hauton JC; Charbonnier M; Cara L; Salles JP
    Eur J Surg Suppl; 1994; (574):117-9. PubMed ID: 7531013
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigen-specific suppressor ("blocking") factors in tumor immunity.
    Hellström KE; Hellström I; Nelson K
    Biomembranes; 1983; 11():365-88. PubMed ID: 6219721
    [No Abstract]   [Full Text] [Related]  

  • 16. The immunotherapy of cancer.
    Parker CW
    Pharmacol Rev; 1973 Jun; 25(2):325-42. PubMed ID: 4581047
    [No Abstract]   [Full Text] [Related]  

  • 17. Suppression of anti-cancer immunity by regulatory T cells: back to the future.
    Orentas RJ; Kohler ME; Johnson BD
    Semin Cancer Biol; 2006 Apr; 16(2):137-49. PubMed ID: 16376101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressor control as a modality of cancer treatment: effect of plasma adsorption with Staphylococcus aureus protein A.
    Ray PK
    Contemp Top Immunobiol; 1985; 15():147-211. PubMed ID: 3161699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoptive cell therapy using in vitro generated human CD4+ CD25+ regulatory t cells with indirect allospecificity to promote donor-specific transplantation tolerance.
    Jiang S; Tsang J; Lechler RI
    Transplant Proc; 2006 Dec; 38(10):3199-201. PubMed ID: 17175221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer immunotherapy using tumor-infiltrating lymphocytes.
    Figlin RA
    Semin Hematol; 1992 Apr; 29(2 Suppl 1):33-5. PubMed ID: 1535456
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.